Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hurler-Scheie, Scheie form of MPS I, or Hurler 2 years after hematopoietic stem cell transplantation~  * Spinal cord compression~ * Has received intrathecal laronidase previously with good response and no significant safety concerns~ * Age greater than 8 years~ * Able to provide legal informed consent~ * Aware of clinical treatment option of observation without treatment or surgical decompression~ * Negative urine pregnancy test at screening (nonsterile females of child-bearing potential who are sexually active only)~Exclusion Criteria:~* Severe (Hurler) form of MPS I~* Desires surgical or medical treatment of spinal cord compression~* Spinal cord compression that warrants immediate surgical intervention~* Pregnancy or lactation~* Hematopoietic stem cell transplantation within 2 years of study enrollment~* Receipt of an investigational drug within 30 days of enrollment~* Infusion reactions to laronidase that required medical intervention, prophylaxis, or altered enzyme administration~* Significant anti-iduronidase antibody titer~* Recent initiation of intravenous laronidase (within past 6 months)~* Presence of cervical subluxation or similar external pathology as the major cause of cord compression symptoms for which surgical intervention should be immediately undertaken

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intrathecal laronidase (Type: EXPERIMENTAL): drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).